|
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Alpha-Fetoprotein, Tumor Marker
Test CodeAFPT
Preferred Specimen
1 mL serum
Minimum Volume
0.5 mL
Instructions
Administration of STRENSIQ may interfere in certain assays and may falsely elevate values. For patients receiving STRENSIQ, consideration should be given to using alternate methods.
Transport Container
Serum separator tube (SST)
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 14 days
Refrigerated: 14 days
Frozen: 45 days
Refrigerated: 14 days
Frozen: 45 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Grossly lipemic
Methodology
Immunoassay (IA)
Setup Schedule
Am Monday-friday
Report Available
3 days
Limitations
Patients who have received monoclonal mouse antibodies may have abnormal results. For any patient taking a high dose of biotin, the specimen should be drawn at least eight hours after the last dose.
Reference Range
Male (ng/mL) | Female (ng/mL) | |
<1 Month* | 0.5-16387.0 | 0.5-18964.0 |
1-11 Months | 0.5-28.3 | 0.5-77.0 |
1-3 Years | 0.5-7.9 | 0.5-11.1 |
>3 Years | <6.1 | <6.1 |
The use of AFP as a tumor marker in pregnant females is not recommended.
Clinical Significance
Elevation of serum AFP above values found in healthy individuals occurs in several malignant diseases, most notably nonseminomatous testicular cancer and primary hepatocellular carcinoma. AFP is not recommended as a screening procedure to detect cancer in the general population.